Peptide and Oligonucleotide CDMO Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)

Peptide and Oligonucleotide CDMO Market – Report Overview

Pacific Business Consulting’s “Peptide and Oligonucleotide CDMO Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of Peptide and Oligonucleotide CDMO market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.

In 2022, the Peptide and Oligonucleotide CDMO market exceeded a valuation of over US$ 2.4 Billion, and it is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) exceeding 8.0% from 2023 to 2030. The market is expected to potentially surpass US$ 4.0 Billion by 2030.

The pharmaceutical industry is experiencing a growing demand for peptides and oligonucleotides as therapeutic agents. Peptides and oligonucleotides have demonstrated potential in treating various conditions, including metabolic disorders, cancer, and genetic diseases. Advances in peptide synthesis, synthetic chemistry, and oligonucleotide manufacturing have expanded the applications of these molecules in therapeutic usage, leading to an increased demand for Contract Development and Manufacturing Organizations (CDMOs) with specialized expertise in these areas.

Key points regarding the growth of peptides and oligonucleotides in the pharmaceutical industry:

Therapeutic Potential:

• Peptides and oligonucleotides show promise in treating a wide range of ailments.
• Innovations in synthesis and manufacturing have facilitated the production and design of complex molecules.

Personalized Medicine:

• The rising trend toward personalized medicine has fueled the need for customized peptide and oligonucleotide therapies.
• CDMOs play a crucial role in the production and development of personalized treatment therapies.

Regulatory Guidelines:

• Regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established guidelines for the manufacturing and development of oligonucleotides and peptides.
• Stringent regulations contribute to the quality and safety of therapeutic agents.

Collaborations and Partnerships:

• There has been a significant increase in collaborations and partnerships across biopharmaceutical companies, especially in the development of peptides, oligonucleotides, and mRNA therapeutics.
• Collaborations aim to enhance capabilities and accelerate research and development.

Investments and Expansion:

• Biopharmaceutical and pharmaceutical companies are making notable investments in the development of peptides for various disease indications.
• EUROAPI’s investment in manufacturing equipment for peptides and oligonucleotides in Frankfurt reflects the industry’s commitment to strengthening operations.

Oligonucleotides Segment Growth:

• The oligonucleotides segment is expected to witness a lucrative Compound Annual Growth Rate (CAGR) due to factors such as increasing pipeline products, growing clinical investment, and a rise in the number of CDMOs entering the industry.
• There is a substantial number of oligonucleotide molecules under development, and pharmaceutical companies are outsourcing manufacturing and development services to expedite drug development timelines.

Overall, the expanding applications of peptides and oligonucleotides, coupled with regulatory support, industry collaborations, and strategic investments, contribute to the positive growth outlook in the pharmaceutical industry.

Leading players in the Peptide and Oligonucleotide CDMO segment, including Aurigene Pharmaceutical Services Ltd., Merck KGaA, EUROAPI, Curia Global, Inc., CordenPharm; Sylentis, S.A., PolyPeptide Group, STA Pharmaceutical Co. Ltd., Bachem and Creative Peptides, are expected to play a crucial role in shaping the future landscape of Peptide and Oligonucleotide CDMO technologies through ongoing innovation.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Peptide and Oligonucleotide CDMO market. It also delves into the analysis of present and prospective market competition within the global Peptide and Oligonucleotide CDMO market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Peptide and Oligonucleotide CDMO market across the 10MM (Ten Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM Peptide and Oligonucleotide CDMO market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

1. Executive Summary: Peptide and Oligonucleotide CDMO
   • Global Market Outlook: Peptide and Oligonucleotide CDMO
2. Competitive Intelligence Analysis: Peptide and Oligonucleotide CDMO
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Peptide and Oligonucleotide CDMO
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Key Marketed Products Profile – Major Approved Products: Peptide and Oligonucleotide CDMO
   • Product Profile
   • Safety and Efficacy
7. Regulatory Landscape
8. Peptide and Oligonucleotide CDMO: Ten Major Market (10MM) – Market Analysis, By Product Class
   • Peptides
   • Oligonucleotides
9. Peptide and Oligonucleotide CDMO: Ten Major Market (10MM) – Market Analysis, By Service
   • Contract Development
   • Contract Manufacturing
10. Peptide and Oligonucleotide CDMO: Ten Major Market (10MM) – Market Analysis, By End User
    • Pharmaceutical Companies
    • Biopharmaceutical Companies
    • Other End Users
11. Peptide and Oligonucleotide CDMO: Ten Major Market (10MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

12. S. Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

13. K. Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

14. Germany Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

15. France Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

16. Italy Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

17. Spain Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

18. Japan Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

19. China Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

20. Australia Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

21. India Peptide and Oligonucleotide CDMO – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Class
      • By Service
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Class
      • By Service
      • By End User

22. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

23. Assumptions and Acronyms Used
24. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
25. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, China, Australia, and India
26. Copyrights and Disclaimer